Publications

5803 Results

HLA-DR protein status predicts survival in patients with diffuse large B cell lymphoma (DLBCL) treated with the MACOP-B chemotherapy regimen

Authors
LM Rimsza;P Farinha;DA Fuchs;H Masoudi;JM Connors;RD Gascoyne
Journal / Conference
Blood 104(11): #3273
Year
2004
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

FC receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800)

Authors
DG Maloney;B Pender-Smith;JM Unger;RM Braziel;J Radich;OW Press;TP Miller;TM Grogan;M LeBlanc;RI Fisher
Journal / Conference
Blood 104(11): #589
Year
2004
Research Committee(s)
Lymphoma
Study Number(s)
S9800

Gene expression profiling, frozen and paraffin section immunohistochemistry, and in situ hybridization for determination of monoclonality in diffuse large B-cell lymphoma

Authors
MW Andres;RA Roberts;DJ Mustacich;RD Gascoyne;DA Fuchs;MX Wang;RM Braziel;WC Chan;TM Grogan;LM Rimsza
Journal / Conference
Blood 104(11): #4553
Year
2004
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Introducing HIPPAA: triple the cost and triple and time for patient recruitment to the SELECT study

Authors
NS Gorby;MS Wolf;CL Bennett
Journal / Conference
Proc of the American Society of Clinical Oncology 23:519 (#6009)
Year
2004
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Acute myeloid leukemia (AML) with t(6;9)(p23;q34) defines a very poor risk leukemia subgroup with distinguishing clinicopathological features: a United States (US) cytogenetics Intergroup study of 62 AML and MDS cases.

Authors
ML Slovak;CD Bloomfield;H Gundacker;G Dewald;FR Appelbaum;RA Larson;MS Tallman;C Willman;Y Ravindranath;TA Alonzo;A Carroll;B Hirsch;S Raimondi;NA Heerema
Journal / Conference
Blood 104(11): #567
Year
2004
Research Committee(s)
Leukemia

Prognostic value of epidermal growth factor receptor expression and small cell phenotype in patients with glioblastoma treated with induction chemotherapy, radiotherapy, 0-6 benzylguanine

Authors
DT Blumenthal;M Quezado;M Santi;A Rapkiewicz;R Ronchetti;EJ Rushing
Journal / Conference
Neuro-Oncology 6(4):350 (PA-03)
Year
2004
Research Committee(s)
Brain
Study Number(s)
S0001

Clinical efficacy of high dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup trial Southwest Oncology Group (SWOG) S9628

Authors
MV Dhodapkar;MA Hussein;E Rasmussen;A Solomon;RA Larson;JJ Crowley;B Barlogie
Journal / Conference
Blood 104(12):3520-3526
Year
2004
Research Committee(s)
Myeloma
Study Number(s)
S9628

Genetic polymorphisms associated with clinical outcome in the Intergroup trial S9321, comparing high dose therapy with standard dose therapy for myelomaon, on behalf of ECOG, SWOG, CALGB, and the bank on a cure

Authors
R Santana-Davila;J Crowley;B Durie;B Barlogie;P Greipp;B Van Ness
Journal / Conference
Blood 104(11): #1495
Year
2004
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/m2 + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of intergroup trial S9321 in the context of IFM 90 and MRC

Authors
J Crowley;R Fonseca;P Greipp;J McCoy;B Barlogie
Journal / Conference
Blood 104(11): #539
Year
2004
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

N9741: Oxaliplatin (Oxal) + CPT-11 or 5-fluorouracil (5FU)/leucovorin (LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study

Authors
RM Goldberg;RF Morton;DJ Sargent;CS Fuchs;RK Ramanathan;SK Williamson;BP Findley
Journal / Conference
ASCO Gastrointestinal Cancers Symposium #215
Year
2004
Research Committee(s)
Gastrointestinal
Study Number(s)
N9741